Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-03-06 00:00:00+00:00 | ABBV | 7 Dividend Kings to Buy for an Uncertain Market Environment | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years... |
2023-03-06 00:00:00+00:00 | ABBV | VTV, ABBV, PFE, BAC: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $884.6 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 726,197,049 to 732,433... |
2023-03-04 00:00:00+00:00 | ABBV | Validea Guru Fundamental Report for ABBV - 3/4/2023 | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-04 00:00:00+00:00 | ABBV | 2 Top Dividend Kings to Buy for the Long Haul | Dividend Kings are among the best stocks that income-seeking investors can turn to in these uncertain days. These companies have been raising their payouts for at least 50 consecutive years, which says something about the strength of their underlying businesses. And beyond the potential for the regular passive income t... |
2023-03-04 00:00:00+00:00 | ABBV | 2 High-Yield Dividend Stocks to Buy in March | Hunting for the next big thing is an exciting investment strategy that usually doesn't work out. Luckily, there's a more reliable way to build wealth through the stock market.
If you're more interested in accumulating wealth than impressing folks with prescient stock market picks, consider these dividend-paying stocks.... |
2023-03-02 00:00:00+00:00 | ABBV | Intel Slashed Its Dividend, But These 3 Yields Are Likely to Continue Rising | In February, Intel (NASDAQ: INTC) rocked the markets with news that it was slashing its dividend by a mammoth 66%. That's a huge blow to investors who counted on that dividend. The danger ultimately comes down to cash flow as Intel was burning through cash from its day-to-day operations, and that is a huge red flag for... |
2023-03-02 00:00:00+00:00 | ABBV | RHHBY vs. ABBV: Which Stock Is the Better Value Option? | Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Everyone has their own methods for finding great val... |
2023-03-02 00:00:00+00:00 | ABBV | Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor | Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn’t have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.
Is this a stock to keep an eye on due to its strong future potential?
Shares fell on March 1 following the company’s fourth-quarter earnings r... |
2023-03-02 00:00:00+00:00 | ABBV | These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio | If you're interested in generating stable dividend income today as well as in the future, you'll need to look for a very particular kind of investment. Most companies don't have the benefit of rock-solid cash flows every quarter, nor do most have the confidence in their long-term growth to continue to give shareholders... |
2023-03-01 00:00:00+00:00 | ABBV | 3 Top Defensive Stocks to Own for a Focus on Quality | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In today’s volatile and uncertain market, investors increasingly seek stable, reliable, and resilient companies to add to their portfolios. Defensive stocks, which are typically associated with companies that operate in industries that provide essential goo... |
2023-03-01 00:00:00+00:00 | ABBV | Validea Guru Fundamental Report for ABBV - 3/1/2023 | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-01 00:00:00+00:00 | ABBV | 3 Value Stocks You'll Regret Not Buying on the Dip | Value stocks are poised for a strong decade. The simple reason is that the Federal Reserve is highly unlikely to spur another growth stock boom by lowering interest rates to the effective floor in the years ahead.
Which value stocks are best positioned to capitalize on this favorable long-term dynamic? These three unde... |
2023-02-27 00:00:00+00:00 | ABBV | Notable Monday Option Activity: WSO, ABBV, BMRN | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Watsco Inc. (Symbol: WSO), where a total of 1,567 contracts have traded so far, representing approximately 156,700 underlying shares. That amounts to about 43.1% of WSO's average daily trading volume over the pa... |
2023-02-27 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +4.4%, compared to the Zacks S&P 500 composite's -1% change. Durin... |
2023-02-27 00:00:00+00:00 | ABBV | 3 High-Yield Dividend Stocks to Buy and Hold Forever | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
High-yield dividend stocks offer relatively high dividend yields compared to the average dividend stock. Generally, I view a high-yield dividend to be above the 4-5% range. Investors can calculate a dividend yield by taking the dividend distribution of a co... |
2023-02-27 00:00:00+00:00 | ABBV | Merck Stock Looks Better Priced Compared To Its Sector Peer | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this g... |
2023-02-27 00:00:00+00:00 | ABBV | AbbVie Gets Positive CHMP Opinion For Upadacitinib For Treatment Of Adults With Crohn's Disease | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... |
2023-02-25 00:00:00+00:00 | ABBV | 3 Biotech Stocks To Watch Ahead Of March 2023 | Biotech stocks represent shares of companies that specialize in the development and commercialization of drugs, therapies, and other medical products based on biological and chemical research. Biotech companies often focus on treating diseases that currently have no cure. Such as cancer, rare genetic disorders, and neu... |
2023-02-25 00:00:00+00:00 | ABBV | Validea Guru Fundamental Report for ABBV - 2/25/2023 | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-02-24 00:00:00+00:00 | ABBV | IWB, ABBV, PEP, PFE: Large Outflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.4 million dollar outflow -- that's a 0.7% decrease week over week (from 127,200,000 to 126,250,000). Among t... |
2023-02-22 00:00:00+00:00 | ABBV | Validea Guru Fundamental Report for ABBV - 2/22/2023 | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with susta... |
2023-02-22 00:00:00+00:00 | ABBV | Want to Get to $1 Million by Retirement? Here's How Much You Should Invest Today. | When you're in your 20s, you might think you don't have enough money to start putting away for retirement, whereas when you're in your 40s or 50s, you might worry that it's too late to start. In a perfect world, you would start putting money aside as early as you can.
But it doesn't always have to be that way, and even... |
2023-02-22 00:00:00+00:00 | ABBV | Analyst Confidence in Eli Lilly Boosted by Product Pipeline | Eli Lilly and Company (NYSE: LLY) is one of the most recognized names in the pharmaceutical industry. Indeed, they are the 12th-largest pharmaceutical company in the world by revenue ($5.5 billion in 2021), and its balance sheet reads as such. But even though LLY has long been a good healthcare stock to hold, analysts ... |
2023-02-22 00:00:00+00:00 | ABBV | This Recession-Proof Company Has a Best-in-Class Dividend | Pharmaceutical companies have a recession-proof business model. The simple reason behind this fact is that people do not choose when they get sick. So, for example, the pharmaceutical industry was largely unaffected by the devastating 2008 global recession. In fact, earnings per share among the industry's biggest names... |
2023-02-22 00:00:00+00:00 | ABBV | Want More Reliable Dividend Income? Buy This Dividend King. | The pharmaceutical industry is ripe for the picking for income investors. That's because the industry enjoys particularly high profit margins, which can fund generous dividends. But as is the case with anything good, there are still risks.
In pharmaceuticals, the biggest risk is the patent expiration of top-performing ... |
2023-02-21 00:00:00+00:00 | ABBV | Johnson & Johnson: Taking The Bull By The Horns? | Johnson & Johnson (NYSE: JNJ) recently filed a shelf registration with the SEC, suggesting it is preparing for the future. The filing is for debt securities, not shares, to be sold on an ongoing basis at a future date that could be as soon as the filing was received. The offering aims to raise capital for general corpo... |
2023-02-20 00:00:00+00:00 | ABBV | 3 Top Dividend Kings to Buy for the Long Haul | For long-term investors, there are not many things better than finding a profitable company paying you to hold shares. Yes, I'm talking about dividends. The best companies can give you annual raises, which can add to substantial investment returns over time. If a company in the S&P 500 can pay and raise its dividend an... |
2023-02-19 00:00:00+00:00 | ABBV | Validea's Top Ten Healthcare Stocks Based On David Dreman - 2/19/2023 | The following are the top rated Healthcare stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
BIONTECH SE - ADR (BNTX) is a large-cap valu... |
2023-02-18 00:00:00+00:00 | ABBV | 3 Dividend Stocks That Should Pay You the Rest of Your Life | Building a portfolio for passive income can be a challenging process, especially if you are just starting out. But it doesn't have to be this way. Investors simply need to buy at least a couple of dozen proven dividend payers across a variety of economic sectors to build a durable portfolio.
Whether you're new to incom... |
2023-02-17 00:00:00+00:00 | ABBV | Daily Dividend Report: NEE,KO,FDX,K,ABBV | The board of directors of NextEra Energy declared a regular quarterly common stock dividend of $0.4675 per share, an approximate 10% increase versus the prior-year comparable quarterly dividend. This increase is consistent with the plan announced in 2022 of targeting roughly 10% annual growth in dividends per share thr... |
2023-02-17 00:00:00+00:00 | ABBV | 5 Dividend Growth Stocks With Upside To Analyst Targets | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-02-17 00:00:00+00:00 | ABBV | 3 Exceptional Dividend Stocks to Buy Right Now | What makes a good dividend stock? One important element is dividend growth.
A company that has lifted its payout year after year is one you may want to have in your portfolio. That's because it's shown its commitment to rewarding shareholders. And that means it's likely to continue along those lines.
The best place to ... |
2023-02-17 00:00:00+00:00 | ABBV | Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 27 cents per share in fourth-quarter 2022, missing both the Zacks Consensus Estimate and our estimate of 28 cents and 29 cents per share, respectively. The reported earnings were in line with the year-ago quarter figure.
Total revenues of $107.2 million ... |
2023-02-17 00:00:00+00:00 | ABBV | 2 Exceptional Growth Stocks to Buy Before the Next Bull Market | No matter how tough it can be to hold onto your investments when they are losing value during bear markets, they always end, and bull markets are liable to kick off shortly thereafter. In fact, investors who keep buying shares of quality companies when the mood on Wall Street is sour are the ones who tend to get a lot ... |
2023-02-16 00:00:00+00:00 | ABBV | Noteworthy Thursday Option Activity: LMT, MGM, ABBV | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Lockheed Martin Corp (Symbol: LMT), where a total of 8,810 contracts have traded so far, representing approximately 881,000 underlying shares. That amounts to about 57.2% of LMT's average daily trading volume over th... |
2023-02-16 00:00:00+00:00 | ABBV | iShares Core S&P U.S. Growth ETF Experiences Big Inflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $105.9 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 136,450... |
2023-02-16 00:00:00+00:00 | ABBV | These 2 Growth Stocks Are Easily Defying the Bear Market | Even if it isn't a good idea to fixate on how your investments perform on a month-to-month basis, it's always a plus when your stocks can shrug off the detrimental impact of a bear market. And with the market falling back sharply during the past 12 months amid rising economic instability, that's no idle concern right n... |
2023-02-16 00:00:00+00:00 | ABBV | Is This the Start of a Nightmare for AbbVie Stock? | With a small army of Wall Street analysts predicting on average that AbbVie's (NYSE: ABBV) revenue will shrink in 2023 as well as in 2024, investors are right to be cautious, and perhaps even a bit skittish. At the same time, the total return of the biopharma's shares is up by 12.4% in the last 12 months, handily beati... |
2023-02-16 00:00:00+00:00 | ABBV | Validea Daily Guru Fundamental Report for ABBV - 2/16/2023 | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout y... |
2023-02-15 00:00:00+00:00 | ABBV | 3 Defensive Growth Stocks to Load Up on in Q1 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In this rather uncertain market, the search for defensive growth stocks is picking up. Indeed, this category of high-quality companies with steady cash flows and growing dividend distributions are sought out in times of turmoil. With interest rates on the r... |
2023-02-15 00:00:00+00:00 | ABBV | Bausch + Lomb to name Brent Saunders as CEO - WSJ | Adds background on Brent Saunders
Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
The leadership change coul... |
2023-02-14 00:00:00+00:00 | ABBV | 2 High-Yielding Dividend Stocks Trading Near 52-Week Lows | A good incentive for buying a strong dividend stock that's underperforming is that you can secure a higher yield. As long as the business's fundamentals remain sound, you can benefit from the better-than-usual payout as well as from the potential capital appreciation it generates if the stock rebounds and rises in valu... |
2023-02-14 00:00:00+00:00 | ABBV | 3 of the BEST Dividend Growth Stocks | Today, I will discuss three of the best dividend growth stocks to invest in. Not only do all these companies increase their dividends at a fast pace, but they are also high-quality companies. One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifecta."
Check out this short video to learn ... |
2023-02-14 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned +0.1% over the past month versus the Zacks S&P 500 composite's +3.6% chan... |
2023-02-14 00:00:00+00:00 | ABBV | Better Buy: Johnson & Johnson or AbbVie? | Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stocks. The companies are favored by income-oriented investors because each has raised its dividend for 50 years or more.
This is a pivotal year for both. Johnson & Johnson is expected to complete the spinoff of its consumer... |
2023-02-14 00:00:00+00:00 | ABBV | Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA | Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children and adolescents with functional constipation (“FC”). The FDA has assigned a PDUFA date of Jun 14, 2023.
Ironwood had fil... |
2023-02-13 00:00:00+00:00 | ABBV | The 7 Most Undervalued Dividend Aristocrats to Buy | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If there’s anything better than having at least some exposure to passive income-providing enterprises, it’s loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[d]ividend aristocrats are stocks of companies that have rai... |
2023-02-13 00:00:00+00:00 | ABBV | AbbVie Has a Mixed Outlook After Mixed Earnings | AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in light on the top line.
Immediately after the report, ABBV stock gapped up 5.8% in pre-market trading. But investors began ... |
2023-02-11 00:00:00+00:00 | ABBV | Here's Exactly How AbbVie Stock Can Beat the Market In 2023 | AbbVie (NYSE: ABBV) stated this week that its earnings could potentially plunge more than 20% this year. The culprit is no secret: The company's top-selling drug, Humira, now faces biosimilar competition in the U.S.
With this forecast, you might think that AbbVie is destined to perform poorly for a while. However, that... |
2023-02-10 00:00:00+00:00 | ABBV | Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO | This week, AstraZeneca AZN and AbbVie ABBV announced their fourth-quarter results, with both companies beating estimates for earnings but missing on sales, like most of their counterparts. Bayer BAYRY announced the appointment of Bill Anderson as its new chief executive officer (CEO). Roche RHHBY and J&J JNJ announced ... |
2023-02-10 00:00:00+00:00 | ABBV | Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics | For the quarter ended December 2022, AbbVie (ABBV) reported revenue of $15.12 billion, up 1.6% over the same period last year. EPS came in at $3.60, compared to $3.31 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.35 billion, representing a surprise of -1.52%. The company ... |
2023-02-10 00:00:00+00:00 | ABBV | SVB Leerink Upgrades AbbVie (ABBV) | On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform.
Analyst Price Forecast Suggests 11.73% Upside
As of February 10, 2023, the average one-year price target for AbbVie is $166.14. The forecasts range from a low of $136.35 to a high of $210.00. The average price targe... |
2023-02-09 00:00:00+00:00 | ABBV | ABBV Makes Bullish Cross Above Critical Moving Average | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. AbbVie Inc shares are currently trading up about 5.5% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q4 2022 Earnings Call Transcript | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q4 2022 Earnings Call
Feb 09, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning. Thank you for standing by. Welcome to the AbbVie fourth quarter 2022earnings conference call [Operator instruct... |
2023-02-09 00:00:00+00:00 | ABBV | US STOCKS-Wall St dips as Treasury yields rise after auction | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Dow down 0.73%, S&P 500 down 0.88%, Nasdaq down 1.02%
Weak demand for $21 bln sale of 30-year Treasury bonds
PepsiCo gains on quarterly profit, sales beat
Disney beats earnings estimates but ends down
Salesforce r... |
2023-02-09 00:00:00+00:00 | ABBV | US STOCKS-Wall St dips as Treasury yields rise; Disney hits 5-month high | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Dow down 0.52%, S&P 500 down 0.56%, Nasdaq... |
2023-02-09 00:00:00+00:00 | ABBV | US STOCKS-Wall St dips as Alphabet extends fall; Disney hits 5-month high | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Indexes down: Dow 0.22%, S&P 0.24%, Nasdaq... |
2023-02-09 00:00:00+00:00 | ABBV | What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings | Dividends are payments made by a corporation to its shareholders. They are typically in the form of cash or additional shares of stock. They are a way for companies to reward their investors for holding their stock. As such, they can provide a steady source of income for investors. Dividend stocks are stocks that pay d... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales | AbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022, beating both the Zacks Consensus Estimate and our estimate, which stood at $3.54. The reported earnings also exceeded the guidance of $3.51-$3.55. Earnings rose 16.9% year over year.
ABBV’s revenues of $15.12 billion missed t... |
2023-02-09 00:00:00+00:00 | ABBV | Vanguard Group Increases Position in AbbVie (ABBV) | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). This represents 8.95% of the company.
In their previous filing dated February 9, 2022 they reported 146.31MM shares and 8.28% of the company, an increase in shares of 8.21% and an increas... |
2023-02-09 00:00:00+00:00 | ABBV | US STOCKS-Wall St rises on robust earnings, Disney hits five-month high | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Indexes up: Dow 0.71%, S&P 0.73%, Nasdaq ... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q4 Earnings Beat Estimates | AbbVie (ABBV) came out with quarterly earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.54 per share. This compares to earnings of $3.31 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.69%. A quarter ago, it was e... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie's 2023 profit forecast misses as Humira faces heat from rivals | Adds shares
Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year.
The company said it expected adjusted profit in the range of ... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie Q4 22 Earnings Conference Call At 9:00 AM ET | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... |
2023-02-09 00:00:00+00:00 | ABBV | AbbVie Q4 Profit Decreases, but beats estimates | (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
The company's earnings totaled $2.47 billion, or $1.38 per share. This compares with $4.04 billion, or $2.26 per share, in last year's fourth quarter.
Excluding items, AbbVie repo... |
2023-02-09 00:00:00+00:00 | ABBV | US STOCKS-Futures rise on earnings optimism, Disney climbs on revamp plan | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Futures up: Dow 0.75%, S&P 0.90%, Nasdaq 1.30%
Feb 9 (Reuters) - U.S. stock index futures rose on Thursday as a slew of strong quarterly earnings lifted sentiment after worries that the Federal Reserve will keep ... |
2023-02-09 00:00:00+00:00 | ABBV | Do Humira Biosimilars Threaten AbbVie's Dividend? | Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats autoimmune diseases, is facing the first of a flood of biosimilar generics hitting the market at lower prices.
Humira is a long... |
2023-02-08 00:00:00+00:00 | ABBV | Vanguard Russell 1000 Growth ETF Experiences Big Inflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Growth ETF (Symbol: VONG) where we have detected an approximate $519.8 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 166,631... |
2023-02-08 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: GPRE, ABBV, K | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Green Plains Inc. (Symbol: GPRE), where a total of 4,115 contracts have traded so far, representing approximately 411,500 underlying shares. That amounts to about 48.2% of GPRE's average daily trading volume ove... |
2023-02-08 00:00:00+00:00 | ABBV | Pre-Market Earnings Report for February 9, 2023 : ABBV, PEP, AZN, PM, SPGI, DUK, BN, TRI, APO, HLT, TU, WTW | The following companies are expected to report earnings prior to market open on 02/09/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. The large cap pharmaceutical company's consensus earnings per share forecast fr... |
2023-02-08 00:00:00+00:00 | ABBV | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund launched on 06/23/2005.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and... |
2023-02-07 00:00:00+00:00 | ABBV | Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings? | AbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales of its immunology and neuroscience products.
Around half of the company’s revenues is expected to be generated from its immunology franchise, consisting of three blockbuster drugs — Humira, Rinvoq and Skyrizi. Humira, whi... |
2023-02-07 00:00:00+00:00 | ABBV | 3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income | Would you like a stock portfolio that generates enough passive income to fuel your retirement dreams? If you answer yes, like most investors, you owe it to yourself to check out the healthcare sector.
In the U.S. alone, healthcare-related spending reached a stunning $4.3 trillion in 2021. Unlike most areas of the econo... |
2023-02-06 00:00:00+00:00 | ABBV | US STOCKS-Wall St edges lower on Fed fears; Tyson Foods slides | By Shubham Batra and Johann M Cherian
Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on when the U.S. Federal Reserve would start cutting rates.
The report on Friday that showed the U.S. economy added j... |
2023-02-06 00:00:00+00:00 | ABBV | AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards? | AbbVie ABBV will report fourth-quarter and full-year 2022 results on Feb 9, before market open. In the last reported quarter, the company delivered an earnings surprise of 2.81%.
This large drugmaker’s performance has been pretty impressive, with its earnings beating estimates in each of the trailing four quarters. The... |
2023-02-06 00:00:00+00:00 | ABBV | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income | Believe it or not, seniors fear running out of cash more than they fear dying.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden years. That's because the traditional ways people manage retirement may no longer provide enough income to meet expenses - and wit... |
2023-02-06 00:00:00+00:00 | ABBV | Abbvie plans to lift $2 billion cap on deals - WSJ | Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.
Chief Executive Officer Richard Gonzalez said the company ... |
2023-02-04 00:00:00+00:00 | ABBV | 2 Stocks Down More Than 6% to Buy Right Now | The three major stock indexes all rose in January as many stocks soared. In fact, some of last year's biggest-losing stocks rebounded in the first month of 2023. But not every stock has taken part in this rally. In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the... |
2023-02-04 00:00:00+00:00 | ABBV | 3 Unstoppable Dividend Stocks to Buy in February | Will the stock market rise or fall in 2023? Income investors can win either way. Any time is a good time to buy solid dividend stocks.
We asked three Motley Fool contributors to identify unstoppable dividend stocks to buy in February. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johns... |
2023-02-03 00:00:00+00:00 | ABBV | AbbVie Q4 Preview: What's in Store? | It’s that time of the year – earnings season.
Earnings season is undoubtedly the most critical period for stocks as companies finally unveil what’s transpired behind closed doors.
So far, we’ve received a surplus of quarterly results, including those from technology titans Apple AAPL, Alphabet GOOGL, and Microsoft MSFT... |
2023-02-03 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -11.4%, compared to the Zacks S&P 500 composite's +9... |
2023-02-03 00:00:00+00:00 | ABBV | 2 Steady Stocks to Buy in a Recession | Many economic analysts continue to predict that a recession will hit the U.S. economy sometime in 2023. Equity markets already experienced a downturn last year due partly to economic troubles, so the possibility of a recession seems even more daunting than it otherwise would be. However, there are ways for investors to... |
2023-02-03 00:00:00+00:00 | ABBV | Is A Rise Imminent For Johnson & Johnson Stock After An 8% Fall In A Month? | Johnson & Johnson stock (NYSE: JNJ) is down 8% in a month, underperforming the broader markets, with the S&P 500 index up 6%. In a recent development, a U.S. appeals court rejected J&J’s attempted use of Texas Two-Step bankruptcy strategy to offload nearly 40,000 lawsuits for its talc products. The company plans to cha... |
2023-02-02 00:00:00+00:00 | ABBV | ABBV March 24th Options Begin Trading | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the March 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 24th contracts and identified one put and one call contract of particular interest.
The put contr... |
2023-02-02 00:00:00+00:00 | ABBV | The 3 Most Undervalued Penny Stocks to Buy in February 2023 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That’s because, with penny stocks, investors’ capital appreciation upside potential is amplified.
Of course, risks are also amplified, making such companies often a... |
2023-02-02 00:00:00+00:00 | ABBV | AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the ... |
2023-02-02 00:00:00+00:00 | ABBV | 2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade | The healthcare industry has proven to be a remarkably resilient place to put capital to work in a wide range of environments. From life-saving medicines and therapies to vaccines, these are just a few examples of the essential products that healthcare companies make that render them particularly defensive investments i... |
2023-02-02 00:00:00+00:00 | ABBV | Merck (MRK) Beats Q4 Earnings and Revenue Estimates | Merck (MRK) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.80 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was exp... |
2023-02-02 00:00:00+00:00 | ABBV | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the mark... |
2023-02-01 00:00:00+00:00 | ABBV | FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high | By Patrick Wingrove
Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... |
2023-02-01 00:00:00+00:00 | ABBV | UK pharma body urges govt to scrap hike in repayment rate for drugmakers | Feb 2 (Reuters) - UK's pharmaceutical trade body on Thursday called for the government to scrap its plans to raise the repayment rates for drugmakers, to avoid possible setbacks in the sector.
Drugmakers that are part of UK's voluntary scheme agreement, which makes branded medicines affordable for people, are required ... |
2023-02-01 00:00:00+00:00 | ABBV | 3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February | Want to know which stocks Warren Buffett owns? First, look at Berkshire Hathaway's 13-F filings to the U.S. Securities and Exchange Commission (SEC). However, those filings won't reveal all of Buffett's stocks.
Many investors don't realize that there's another group of stocks Buffett owns in addition to the stocks list... |
2023-02-01 00:00:00+00:00 | ABBV | Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints | Amgen AMGN reported fourth-quarter 2022 earnings of $4.09 per share, which beat the Zacks Consensus Estimate of $4.04. Earnings declined 7% year over year due to a lower operating margin.
Total revenues of $6.84 billion also beat the Zacks Consensus Estimate of $6.74 billion as well as our estimate of $6.66 billion. To... |
2023-01-31 00:00:00+00:00 | ABBV | Amgen revenue falls slightly as Lilly COVID deal contributes less | Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co. LLY.N
Amgen reported revenue of $6.84 billion in the quarter, down from $6.8... |
2023-01-31 00:00:00+00:00 | ABBV | Here's What To Expect From Merck's Q4 | Merck (NYSE: MRK) is scheduled to report its Q4 2022 results on Thursday, February 2. We expect MRK stock to trade sideways, with its revenue likely falling slightly below and earnings marginally above the street estimates. Although the company should benefit from continued market share gains for Keytruda and Gardasil,... |
2023-01-31 00:00:00+00:00 | ABBV | IWF, ABBV, HD, UNP: Large Outflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $1.1 billion dollar outflow -- that's a 1.8% decrease week over week (from 267,900,000 to 263,100,000). Am... |
2023-01-31 00:00:00+00:00 | ABBV | FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high | By Patrick Wingrove
Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... |
2023-01-31 00:00:00+00:00 | ABBV | Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates | Pfizer (PFE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 10.68%. A quarter ago, it was e... |
2023-01-30 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Moves -0.43%: What You Should Know | AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.3%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 5.51%.
Heading into today, shares of the drugmaker had lost 9.49% over the past month, la... |
2023-01-30 00:00:00+00:00 | ABBV | Dividends for Stability, Safety in a Mixed Market | A
few weeks ago, we talked to you about the 2023 stock market outlooks from a number of Wall Street strategists. By and large, those experts were more optimistic about this year than last, but many believe we'll still have to ensure more turbulence before reaching clearer skies.
This week, we'll discuss one way to navi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.